{
    "clinical_study": {
        "@rank": "93993", 
        "arm_group": {
            "arm_group_label": "BBI503", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This is an open label, single arm dose escalation study of BBI503 in adult patients with\n      advanced solid tumors."
        }, 
        "brief_title": "A Phase I Clinical Study of BBI503 in Adult Patients With Advanced Solid Tumors", 
        "condition": "Cancer, Advanced Solid Tumors", 
        "condition_browse": {
            "mesh_term": "Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Signed written informed consent must be obtained and documented according to\n             International Conference on Harmonization (ICH)- Good Clinical Practice (GCP), the\n             local regulatory requirements, and permission to use private health information in\n             accordance with the Health Insurance Portability and Accountability Act (HIPPA) prior\n             to study-specific screening procedures\n\n          2. A histologically or cytologically confirmed solid tumor that is metastatic,\n             unresectable, or recurrent and for which standard curative or palliative therapies do\n             not exist or are no longer effective.\n\n          3. \u2265 18 years of age\n\n          4. Measurable disease as defined by Response Evaluation Criteria in Solid Tumors\n             (RECIST, see Section 9)\n\n          5. Karnofsky performance status \u2265 70% (Section 14)\n\n          6. Male or female patients of child-producing potential must agree to use contraception\n             or avoidance of pregnancy measures during the study and for 30 days after the last\n             BBI503 dose\n\n          7. Females of childbearing potential must have a negative serum pregnancy test\n\n          8. Aspartate transaminase (AST) and alanine transaminase (ALT) < or equal to 1.5 \u00d7 upper\n             limit of normal (ULN)\n\n          9. Hemoglobin (Hgb) \u2265 10 g/dl\n\n         10. Total bilirubin < or equal to 1.5 \u00d7 ULN\n\n         11. Creatinine < or equal to 1.5 x ULN or creatinine clearance > 60 mL/min/1.73 m2 for\n             patients with creatinine levels above institutional normal\n\n         12. Absolute neutrophil count < or equal to 1.5 x 109/L\n\n         13. Platelets \u2265 100 x 109/L\n\n         14. Life expectancy \u2265 3 months\n\n        Exclusion Criteria:\n\n          1. Anti-cancer chemotherapy, radiotherapy, immunotherapy, or investigational agents\n             within four weeks of first dose with the exception for a single dose radiation up to\n             8 Gray (equal to 800 RAD) with palliative intent for pain control up to 14 days\n             before beginning the administration of BBI503\n\n          2. Surgery within 4 weeks prior to first dose\n\n          3. Any known untreated brain metastases.  Treated subjects must be stable for 4 weeks\n             after completion of that treatment, with image documentation required.  Patients must\n             have no clinical symptoms from brain metastases and must be either off steroids or on\n             a stable dose of steroids for at least 2 weeks prior to protocol enrollment. Patients\n             with known leptomeningeal metastases are excluded, even if treated.\n\n          4. Pregnant or breastfeeding\n\n          5. Significant gastrointestinal disorder(s), in the opinion of the Principal\n             Investigator, (e.g., Crohn's disease, ulcerative colitis, extensive gastric resection\n             and small intestinal resection)\n\n          6. Unable or unwilling to swallow BBI503 capsules daily\n\n          7. Uncontrolled intercurrent illness including, but not limited to ongoing or active\n             infection, clinically significant non-healing or healing wounds, symptomatic\n             congestive heart failure, unstable angina pectoris, cardiac arrhythmia, significant\n             pulmonary disease (shortness of breath at rest or mild exertion), uncontrolled\n             infection or psychiatric illness/social situations that would limit compliance with\n             study requirements"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 24, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01781455", 
            "org_study_id": "BBI503-101"
        }, 
        "intervention": {
            "arm_group_label": "BBI503", 
            "intervention_name": "BBI503", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "February 3, 2014", 
        "location": [
            {
                "contact": {
                    "email": "Siobhan_Collins@dfci.harvard.edu", 
                    "last_name": "Siobhan Collins", 
                    "phone": "617-632-2580"
                }, 
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02215"
                    }, 
                    "name": "Dana Farber Cancer Institute"
                }, 
                "investigator": {
                    "last_name": "Joyce F. Liu, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "kvitale3@mgh.harvard.edu", 
                    "last_name": "Kelly Vitale", 
                    "phone": "617-724-2578"
                }, 
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02114"
                    }, 
                    "name": "Massachusetts General Hospital"
                }, 
                "investigator": {
                    "last_name": "Gregory M. Cote, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "PhaseIOncologyTrials@bidmc.harvard.edu", 
                    "last_name": "Kimiko Kossler", 
                    "phone": "617-632-9280"
                }, 
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02215"
                    }, 
                    "name": "Beth Israel Deaconess Medical Center"
                }, 
                "investigator": {
                    "last_name": "James W. Mier, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "The University of Michigan Cancer AnswerLine", 
                    "phone": "800-865-1125"
                }, 
                "facility": {
                    "address": {
                        "city": "Ann Arbor", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "48109"
                    }, 
                    "name": "University of Michigan Comprehensive Cancer Center"
                }, 
                "investigator": {
                    "last_name": "David C Smith, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "jkueber@ghs.org", 
                    "last_name": "Jan Kueber, RN", 
                    "phone": "864-455-3600"
                }, 
                "facility": {
                    "address": {
                        "city": "Greenville", 
                        "country": "United States", 
                        "state": "South Carolina", 
                        "zip": "29605"
                    }, 
                    "name": "Institute for Translational Oncology Research, Greenville Hospital System"
                }, 
                "investigator": [
                    {
                        "last_name": "William J Edenfield, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Joe J Stephenson, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Scott Laurie, MD", 
                    "phone": "613-737-7700"
                }, 
                "facility": {
                    "address": {
                        "city": "Ottawa", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "K1H 8L6"
                    }, 
                    "name": "Ottawa Hospital Cancer Centre"
                }, 
                "investigator": [
                    {
                        "last_name": "Scott Laurie, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Derek Jonker, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Canada"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase I Clinical Study of BBI503 in Adult Patients With Advanced Solid Tumors", 
        "other_outcome": [
            {
                "measure": "Progression Free Survival", 
                "safety_issue": "No", 
                "time_frame": "The time the participant stays on study until progression will be measured and recorded.  This is estimated to be approximately 4 months."
            }, 
            {
                "description": "The time of overall survival will be measured and recorded for each participant.", 
                "measure": "Overall Survival", 
                "safety_issue": "No", 
                "time_frame": "Participant follow-up for overall survival will occur approximately quarterly for the first year the participant is off study, twice during the second year, and once per year thereafter for up to approximately 100 months."
            }
        ], 
        "overall_official": [
            {
                "affiliation": "Greenville Hospital System, ITOR", 
                "last_name": "William J Edenfield, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Ottawa Hospital Cancer Centre", 
                "last_name": "Scott Laurie, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Canada: Health Canada"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Assessment of safety of BBI503 by reporting of adverse events and serious adverse events.", 
                "measure": "Number of participants with Adverse Events as a Measure of Safety and Tolerability", 
                "safety_issue": "Yes", 
                "time_frame": "Adverse events will be assessed at baseline, while the participant is taking BBI503, and for 30 days after stopping therapy.  The average length of this duration is expected to be approximately 4 months."
            }, 
            {
                "measure": "Determine recommended Phase 2 dose", 
                "safety_issue": "No", 
                "time_frame": "Up to treatment discontinuation + 30 days with an estimated treatment duration of 4 weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01781455"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Blood sampling to assess the pharmacokinetic profile (Area under the curve) of BBI503.", 
                "measure": "Assess the pharmacokinetic profile (Area under the curve) of BBI503", 
                "safety_issue": "No", 
                "time_frame": "During the first 28 days of treatment"
            }, 
            {
                "description": "Tumor Biopsy(s) to provide information on analysis of the targets and downstream genes/ effect of BBI503 on cancer stem cells through immunohistochemistry.", 
                "measure": "Assess pharmacodynamic activity", 
                "safety_issue": "No", 
                "time_frame": "During the first 28 days of treatment"
            }, 
            {
                "description": "To assess the preliminary anti-tumor activity of BBI503.", 
                "measure": "Anti-tumor activity", 
                "safety_issue": "No", 
                "time_frame": "Participants will be assessed every eight weeks for anti-tumor activity."
            }
        ], 
        "source": "Boston Biomedical, Inc", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Boston Biomedical, Inc", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2012", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}